Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However...
Main Authors: | Yan Lin, Huan-Wei Liang, Yang Liu, Xin-Bin Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1264912/full |
Similar Items
-
Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
by: Sanne J. M. Hoefnagel, et al.
Published: (2022-09-01) -
NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)
by: A. M. Mudunov
Published: (2017-11-01) -
Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real-World Experience within an Integrated Health System
by: Hyunjee V. Kwak, et al.
Published: (2023-11-01) -
Black Twig Borer, Xylosandrus compactus (Eichhoff) (Insecta: Coleoptera: Scolytidae)
by: Wayne N. Dixon, et al.
Published: (2023-01-01) -
Diode 577-nm Laser Plus Tioconazole 28% Nail Solution versus Topical Tioconazole 28% Nail Solution Alone in Treatment of Onychomycosis
by: Sara Yossif, et al.
Published: (2023-10-01)